Liquid Biopsy Market Analysis, By Key Companies (Guardant Health, Inc. Trovagene, Inc. RainDance Technologies, Inc. Agena Bioscience Inc.) by Biomarker Types and Other Biomarker (Circulating Rna And Proteins), by Application (Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application), by Sample (Blood Sample, Urine Sample, Other) And End User (Hospitals and Laboratories, Academic And Research Centers, Other End Users) - Forecast to 2022
Pune, India -- (SBWIRE) -- 10/24/2017 -- The global Liquid Biopsy market is currently valued at $ 3950 million and will reach $ 17,372.28 million growing at a CAGR of 28%. A liquid biopsy is a largely non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring diseases such as cancer. Liquid biopsy is the direct clinical application of two advances in medical science namely human genome sequencing and rising sensitivity of detecting techniques and assays.
The growth factors responsible for this explosive growth are liquid biopsy is a comparatively painless and non-invasive technique which provides early real time high precision detection of diseases which could be used for monitoring and designing effective treatment strategies based on the real time molecular assessment for the progression of the disease. Other factors driving the liquid biopsy market are lifestyle changes and environmental factors such as rising investment in research and development and collaborations between companies and public organizations, rise in population particularly geriatric population, rising expenditure on health etc. The technique also has other advantages over traditional tissue biopsy such as potential applications to cardiovascular diseases, autoimmune diseases etc.
The restraints include the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. Also not all cancer patients benefit from early detection as some cancers such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Get a Copy of Sample Report @ https://www.marketresearchfuture.com/sample-request/710
Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period
Key Players for Global Liquid Biopsy market:
- Guardant Health, Inc.
- Trovagene, Inc.
- RainDance Technologies, Inc.
- Agena Bioscience Inc.
- Admera Health
- Biocept, Inc.
- Circulogene Theranostics
- Inivata Ltd.
- SAGA Diagnostics AB
- Exosome Diagnostics
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centers and others.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market
Regional Analysis of Global Liquid Biopsy market:
Globally North America is the largest market for Global Liquid Biopsy market. Europe is the second-largest market for Global Liquid Biopsy market. However the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future. North America accounted for the largest market share of 37.95% in 2016 accounting for a market value of 1,499.10 million in 2016. Asia pacific is the fastest growing market which is growing at a CAGR of 28.8%.
The report for Global Liquid Biopsy market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
We are thankful for the support and assistance from Global Liquid Biopsy Market Research Report- Forecast to 2022 chain related technical experts and marketing experts during Research Team survey and interviews.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.